Correlation of Preoperative Ki67 and Serum CA15.3 Levels with Outcome in Early Breast Cancers - a Multi Institutional Study |
Rasmy, A
(Medical Oncology Department, Zagazig University)
Abozeed, W (Clinical Oncology Department, Faculty of Medicine, Mansoura University) Elsamany, S (Medical Oncology Department, Oncology Centre, Mansoura University) El Baiomy, M (Medical Oncology Department, Oncology Centre, Mansoura University) Nashwa, A (Medical Oncology Unit, King Khaled University Hospital, King Saud University) Amrallah, A (Medical Oncology Department, Zagazig University) Hasaan, E (Adult Oncology Department, Oncology Center, King Fahad Specialist Hospital) Alzahrani, A (King Abdullah Medical City) Faris, M (Adult Oncology Department, Oncology Center, King Fahad Specialist Hospital) Alsaleh, K (Medical Oncology Unit, King Khaled University Hospital, King Saud University) AlFaraj, A (Medical Oncology Unit, King Khaled University Hospital, King Saud University) |
1 | Sokoll L, Chan D (2004). Clinical chemistry: Tumor markers. In: Abeloff MD, Armitage JO, Niederhuber JE,Kastan MB, McKenna WG, editors. In Abeloff Clinical Oncology. 3rd ed. Pennsylvania: Elsevier Churchill Livingston. |
2 | Stuart-Harris R, Caldas C, Pinder S, et al (2008). Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast, 17, 323-34. DOI |
3 | Tampellini M, Berruti A, Gerbino A, et al (1997). The relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer, 75, 698-702. DOI |
4 | Tanei T, Shimomura A, Shimazu K, et al (2011). Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol, 37, 155-61. DOI |
5 | Waxman J (1995). Tumor markers. Quart J Med, 88, 233-41. |
6 | Yerushalmi R, Woods R, Ravdin P, et al (2010). Ki67 in breast cancer:prognostic and predictive potential. Lancet Oncol, 11, 174-83. DOI |
7 | Canizares F, Sola J, Perez M, et al (2001). Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol, 22, 273-281. DOI |
8 | Chu W, and Ryu D, (2016). Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer. Ann Surg Treat Res, 90, 57-63. DOI |
9 | Coleman M, Quaresma M, Berrino F, et al (2008). Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol, 9, 730-56. DOI |
10 | Colozza M, Azambuja E, Cardoso F, et al (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol, 16, 1723-39. DOI |
11 | De Azambuja E, Cardoso F, de Castro G, et al (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer, 96, 1504-13. DOI |
12 | DeVita, Hellman and Rosenberg's Cancer (2014). Principles & Practice of Oncology, 10th edition, 1632. |
13 | Gasparini G, (1998). Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Res Treat, 52, 321-31. DOI |
14 | Duffy M, Duggan C, Keane R, et al (2004). High preoperative CA 15-3 concentrations predict adverse outcome in nodenegative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem, 50, 559-63. DOI |
15 | Fotinos-Ioannis D, Anastasia K, Anna G, et al (2015). Early-Stage breast cancer in the elderly: confronting an old clinical problem. J Breast Cancer, 18, 207-17. DOI |
16 | Gasparini G, Toi M, Gion M, et al (1997). Prognostic significance of vascular endothelial growth factor protein in nodenegative breast carcinoma. J Natl Cancer Inst, 89, 139-47. DOI |
17 | Kurebayashi J, Kanomata N, Shimo T, et al (2014). Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Breast Cancer, 21, 214-22. DOI |
18 | Hashim Z, (2014). The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status. Int J Immunopathol Pharmacol, 27, 45-51. DOI |
19 | Jones RL, Salter J, A'Hern R, et al (2009). The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat, 116, 53-68. DOI |
20 | Kobayashi T, Iwaya K, Moriya T, et al (2013). A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer. BMC Clin Pathol, 6, 13-5. |
21 | Molina R, Filella X, Alicarte J, et al (2003). Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res, 23, 1035-41. |
22 | Molina R, Jo J, Filella X, et al (1998). c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat, 51, 109-19. DOI |
23 | Sandri M, Salvatici M, Botteri E, et al (2015). Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat, 132, 317-26. |
24 | Shao Y, Sun X, He Y, et al (2015). Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLoS ONE, 10, 133830. |
25 | Gnant M, Harbeck N, Thomssen C (2011). St. Gallen summary of the Consensus Discussion. Breast Care, 6, 136-41. DOI |